Track market-moving stories before they get noisy

Kurv Investment Management's Howard Chan talks about his firm's KMEM ETF and how it offers investors exposure to global AI memory businesses. He then talks about memory's role in AI infrastructure by highlighting chipmakers Micron (MU), Samsung and SK Hynix.

The Amgen logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

SummaryCompaniesJudge says Amgen likely to face significant, irreparable harmEnbrel price was capped at $31,200 annually, list price tops $100,000Colorado declined to commentJuly 1 (Reuters) - A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's (AMGN.O), opens new tab blockbuster arthritis drug Enbrel, a first-of-its-kind ‌move by a U.S. state.

In granting a preliminary injunction, Chief Judge Daniel Domenico of the Denver federal court said Amgen would likely face significant and irreparable harm from charging lower prices, adding that it ​could affect the drugmaker's negotiations for future contracts with wholesalers and distributors.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Domenico said ​that "as a matter of basic economic logic, Amgen is likely to ⁠be significantly harmed by a cap on the price of its product, even if ​the cap applies unevenly" within the supply chain.

He also said that while Colorado had a ​legitimate interest in helping patients afford Enbrel, and could try doing so through subsidies or negotiations to lower prices as the federal government has done, "capping the price of a patented drug" was not an ​option.

In October, the Colorado Prescription Drug Affordability Board capped Enbrel prices at $600 for a ​50-milligram weekly dose, or $31,200 per year, effective on January 1, 2027.

The list price of Enbrel exceeds $100,000 per ‌year. ⁠Amgen had until July 5 to decide whether to continue selling the drug in Colorado.

Genna Morton, a spokeswoman for Colorado's Division of Insurance, said the agency cannot comment on pending litigation. Amgen and its lawyers did not immediately respond to requests for comment.

The U.S. ​pays about three times ​as much as other ⁠high-income countries for branded drugs, and the federal government and states have pursued policies to keep prices down.

Enbrel, whose chemical name is ​etanercept, is used to treat arthritis and plaque psoriasis. It is ​one of ⁠Amgen's biggest drugs, accounting for $2.23 billion of sales in 2025.

The Thousand Oaks, California-based drugmaker said Colorado's cap conflicted with federal patent law, violated its due process rights under the U.S. ⁠Constitution and ​threatened patients' access to needed treatment.

Domenico was appointed ​to the bench by Donald Trump. The U.S. president has nominated Domenico to join the 10th U.S. Circuit Court of ​Appeals, whose jurisdiction includes Colorado.

Reporting by Jonathan Stempel in New York; Editing by Mark Porter

Our Standards: The Thomson Reuters Trust Principles., opens new tab

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MercadoLibre, Inc. (“MercadoLibre” or the “Company”) (NASDAQ: MELI) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON MERCADOLIBRE, INC. (MELI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happened?On.

Choosing between established stability and high-tech growth often defines a portfolio. Whether you prefer the diversified reach of Abbott Laboratories (ABT +1.49%) or the specialized dominance of Intuitive Surgical (ISRG +1.17%), both offer compelling paths.

Abbott operates a broad healthcare empire spanning baby formula to heart valves, providing steady cash flows across market cycles. Intuitive Surgical focuses intensely on robotic-assisted surgery, benefiting from an ecosystem that generates significant recurring revenue. This comparison involves weighing broad diversification against narrow, high-margin specialization in the healthcare sector.

The case for Abbott LaboratoriesAbbott Laboratories operates across four primary segments, including medical devices, diagnostics, nutrition, and established pharmaceuticals. It sells these products globally to a diverse customer base of wholesalers, hospitals, clinics, and government agencies. In March 2026, the company completed its acquisition of Exact Sciences Corporation, a move designed to expand its presence in the cancer diagnostics market.

Financial results show the scale of these operations. In FY 2025, revenue reached nearly $44.3 billion, up roughly 5.7% from the previous year. Net income for the same period was close to $6.5 billion, while the company maintained a net margin of approximately 14.7%.

As an established player among medical device stocks, Abbott maintains a sturdy balance sheet. According to its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.3x, which measures total debt relative to shareholders’ equity. The current ratio, which gauges the ability to cover short-term obligations with short-term assets, stood at approximately 1.6x, and the company generated roughly $7.4 billion in free cash flow.

The case for Intuitive SurgicalIntuitive Surgical provides a robotic-assisted surgical ecosystem, primarily through its da Vinci and Ion platforms. The company generates revenue by selling these systems to hospitals and then providing the ongoing instruments, accessories, and services required for procedures. In early 2026, the company strengthened its international footprint by bringing several European distribution businesses in-house through strategic acquisitions.

Growth has remained robust for the robotic surgery pioneer. In FY 2025, revenue reached close to $10.1 billion, which was a significant increase of approximately 20.5% over the prior year. Net income for the period was roughly $2.9 billion, supported by a healthy net margin of nearly 28.4%.

Financial health remains a core strength for the company. As of its December 2025 balance sheet, the debt-to-equity ratio was 0.0x, indicating the company has virtually no debt relative to its equity. The current ratio was approximately 4.9x, and free cash flow reached nearly $2.5 billion. Note that stock-based compensation accounted for roughly 26.0% of operating cash flow, thereby inflating reported cash generation, since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparisonAbbott Laboratories faces several headwinds, including product liability and legal exposure related to its infant formula and spinal cord stimulators. The $20 billion in debt incurred to acquire Exact Sciences has also significantly increased its total indebtedness, reducing financial flexibility and increasing its sensitivity to interest rate changes. Furthermore, the company remains under intense regulatory scrutiny from the FDA regarding its manufacturing and marketing claims.

Intuitive Surgical must navigate complex global regulations and potential delays in regulatory reviews for its new products. The company is also vulnerable to cybersecurity threats that could compromise its connected surgical systems or patient data privacy. Additionally, the robotic-assisted surgery market is increasingly competitive, and consolidation among healthcare providers could lead to downward pressure on system pricing and profit margins.

Valuation comparisonAbbott Laboratories offers a significantly lower entry point based on sales and future earnings estimates compared to the premium valuation assigned to Intuitive Surgical.

MetricAbbott LaboratoriesIntuitive SurgicalSector BenchmarkForward P/E17.1x38.7x24.8xP/S ratio3.7x14.2xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Both of these companies appear to be good choices for a long-term investor’s portfolio. Both are leaders in their medical technology niches, and both have strong performance and growth potential. And although one may have slightly higher growth potential than the other, there are two other key differences driving investors’ choice.

Intuitive Surgical is the maker of the da Vinci robotic surgery platform. It’s installed in over 7,500 hospitals worldwide, and this technology has treated more than 20 million patients. It trades at a premium valuation relative to the broader medical technology and healthcare sectors, largely driven by its “razor-and-blades” model of recurring revenue from the sale of its instruments and accessories. It also benefits from high switching costs. However, it does not pay a dividend.

Abbott Laboratories is diversified. Its operations include pharmaceuticals, diagnostics, nutritional products, and medical devices. Its FreeStyle Libre continuous glucose monitoring system has driven growth in recent years, and its March 2026 acquisition of Exact Sciences represents another major expansion into cancer diagnosis. Abbott has a long track record of dividend increases, demonstrating it has the cash flow and stability to support them.

Investors seeking higher growth potential may prefer Intuitive Surgical. But for those looking for steady growth and dividend income, Abbott Laboratories is the stock I would choose.

Characteristics and Risks of Standardized Options: https://bit.ly/2v9tH6D. ServiceNow (NOW) has taken a beating ever since the SaaS-pocalypse after investors expressed AI disruption fears.

Plug Power stock is under selling pressure. Why are PLUG shares declining? What Is Driving Plug Power’s Growth in Denmark?The recent spark for PLUG has been its progress in Denmark, where the company said it completed installation, commissioning, site acceptance testing and handover of a 5 MW GenEco PEM electrolyzer system at the Måde Power-to-X facility in Esbjerg, moving the site into active hydrogen production.

At full capacity, Plug expects about 550 metric tons of green hydrogen per year (roughly 1,500 truckloads), with output certified as Renewable Fuel of Non-Biological Origin under the ISCC scheme.

Plug has been leaning hard into "repeatable execution," highlighting a fully containerized design intended to reduce on-site complexity and accelerate production readiness, a message CEO José Luis Crespo has tied to more disciplined growth.

Plug Power Stock: Key Levels To WatchFrom a longer-term trend view, the stock is trying to hold its base above the 200-day moving average ($2.62) but is still trading below the faster trend gauges—about 6.9% under the 20-day SMA ($2.86) and 17.7% under the 50-day SMA ($3.24). That setup often means rallies can run into overhead supply near those moving averages unless buyers can string together a few stronger closes.

Momentum is best framed by MACD right now: it’s below its signal line and the histogram is negative, which points to upside pressure fading versus the prior upswing unless it can reclaim that baseline. In plain terms, MACD compares shorter- and longer-term trend momentum, and being below the signal line usually means the push higher is losing steam.

The crossover picture stays split, with the 20-day SMA below the 50-day SMA (bearish near-term structure) but the 50-day SMA still above the 200-day SMA, keeping the September 2025 golden cross intact. Zooming out, the stock remains in a wide 52-week range between $1.24 and $4.58, with April’s swing low and June’s swing high still framing the current consolidation.

Key Resistance: $2.86 — the 20-day SMA is nearby and can act as the first "sell zone" if rebounds fade Key Support: $2.62 — the 200-day SMA is close and has been a key line-in-the-sand for the longer-term trend What Is Plug Power’s Green Hydrogen Strategy?Plug Power is building an end-to-end green hydrogen ecosystem, spanning production, storage, and delivery through to energy generation. The company’s strategy is to build and operate green hydrogen highways across North America and Europe.

That’s why the Denmark handover is a meaningful data point: it’s a real operating proof that Plug can deliver electrolyzer projects into active production, not just announce them. Management has also been emphasizing a more repeatable, containerized design approach aimed at reducing on-site complexity and speeding time-to-production, which is central to rebuilding confidence after a volatile 12 months.

Plug Power Stock Price Movement on WednesdayPLUG Stock Price Activity: Plug Power shares were down 1.85% at $2.66 at the time of publication on Wednesday, according to Benzinga Pro data.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

-

SAN MATEO, Calif.--(BUSINESS WIRE)--On Friday, July 31st at approximately 8:30 a.m. Eastern Time, Franklin Resources, Inc. (the “Company”) [NYSE:BEN] will release its third quarter operating results. A written commentary on the results will also be available via investors.franklinresources.com at approximately 8:30 a.m. Eastern Time.

In addition, Jenny Johnson, CEO; Matthew Nicholls, Co-President, CFO and COO; and Daniel Gamba, Co-President and Chief Commercial Officer, will lead a live teleconference at 10:00 a.m. Eastern Time to answer questions.

Access to the teleconference will be available via investors.franklinresources.com or by dialing (+1) 877-407-0989 in North America or (+1) 201-389-0921 in other locations. A replay of the teleconference can also be accessed by calling (+1) 877-660-6853 in North America or (+1) 201-612-7415 in other locations using access code 13761569 after 2:00 p.m. Eastern Time on July 31, 2026 through August 7, 2026, or via investors.franklinresources.com. Analysts and investors are encouraged to review the Company's recent filings with the U.S. Securities and Exchange Commission and to contact Investor Relations at [email protected] before the live teleconference for any clarifications or questions related to the earnings release or written commentary.

About Franklin Templeton

Franklin Templeton is a trusted investment partner, delivering tailored solutions that align with clients’ strategic goals. With deep portfolio management expertise across public and private markets, we combine investment excellence with cutting-edge technology. Since our founding in 1947, we have empowered clients through strategic partnership, forward-looking insights, and continuous innovation – providing the tools and resources to navigate change and capture opportunity.

With $1.78 trillion in assets under management as of May 31, 2026, Franklin Templeton operates globally in more than 35 countries.

To learn more, visit franklintempleton.com and follow us on LinkedIn.

Franklin Resources, Inc. [NYSE: BEN]

More News From Franklin Resources, Inc.

Back to Newsroom

NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the “Class Period”), of the important July 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid’s business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid’s manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

July 01, 2026 16:00 ET  | Source: Vaxart, Inc.

Company to Appoint Mutually Agreed Upon Independent Director; Forms Stockholder Engagement and Clinical and Regulatory Affairs Committees 

Stockholder Group Withdraws Director Nominations

SOUTH SAN FRANCISCO, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced a resolution to the proxy contest in connection with the Company’s 2026 Annual Meeting of Stockholders, reflecting a commitment to value creation, strong corporate governance and constructive engagement with stockholders.

Vaxart will initiate a search for an additional independent director to be conducted within 90 days of the conclusion of the 2026 Annual Meeting. Pursuant to a cooperation agreement between the Company and stockholders Daniel P. Houle, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD, Patrice Raffy, Marc Eustace Pereira and Q3 Nominees Pty Ltd. (the “Stockholder Group”), the Company will work with the Stockholder Group to identify a mutually agreeable candidate to be appointed to the Board. The Stockholder Group has also agreed under the cooperation agreement to withdraw the director nominations of Mr. Houle, Dr. Silverberg and Dr. Wallace in connection with the 2026 Annual Meeting.

The cooperation agreement additionally provides for the formation of a Stockholder Engagement Committee and a Clinical and Regulatory Affairs Committee, Board committee refreshment, including the selection of new chairs for the Nominating and Governance and Compensation Committees, the adoption of director stock ownership and resignation policies, as well as certain customary standstill, voting, engagement and other provisions.

“Vaxart is approaching a series of important value-inflection milestones, and these actions enable the Company to move forward with a unified focus on executing its strategy,” said W. Mark Watson, Lead Independent Director of Vaxart’s Board. “We appreciate the constructive dialogue with the Stockholder Group toward our shared goal of creating value and are pleased to resolve our proxy contest so we can dedicate our full resources and attention to advancing our pipeline with stockholder interests in mind. We believe these governance enhancements will reinforce the continuity of experienced oversight needed as Vaxart enters its next phase of growth.”

The Stockholder Group commented, “We are pleased to have reached an agreement that enhances Vaxart’s corporate governance and engagement with stockholders. We have long believed in the potential of Vaxart’s science and differentiated oral vaccine platform. The actions announced today strengthen Board oversight and accountability and give us confidence that Vaxart is positioned to unlock significant value for stockholders.”

The cooperation agreement will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.

Goodwin Procter LLP and Thompson Hine LLP are serving as legal advisors and Joele Frank, Wilkinson Brimmer Katcher is serving as strategic communications advisor to Vaxart. Olshan Frome Wolosky LLP is serving as legal advisor to the Stockholder Group.

About Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Cautionary Language Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions created by those sections, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” “target,” “seek,” “intend,” “may,” “predict,” “project,” “would,” and other words and terms of similar meaning. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K, as amended, and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Important Additional Information and Where to Find It

 Vaxart has filed a definitive proxy statement and form of white proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://investors.vaxart.com/financials-filings/sec-filings.

Investor Contact

Michael Fein
Campaign Management
(855) 264-1527

Media Contact

Aaron Palash / Adam Pollack
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Robinhood Markets stock is among today’s top performers. What’s behind HOOD gains? Robinhood Chain Goes LiveAlongside the network launch, the company said its tokenized stock offering is now fully operational, giving users in more than 120 countries the ability to trade equity tokens at any hour and plug them into lending and collateral applications.

Robinhood also rolled out a lending product called Robinhood Earn, through which users can put its USDG stablecoin to work via a self-custody wallet and collect a projected annual return of 7%.

Robinhood Live Event TodayRobinhood has stated it will present “The World is Flat,” a live event hosted at the historic Old Royal Naval College in London by CEO Vlad Tenev and SVP of Crypto and International Johann Kerbrat. The livestream will begin at 2 p.m. ET.

June Trading VolumesThe product announcements build on a strong recent trading backdrop. Through June 25, Robinhood reported equity notional trading volumes of about $343 billion, options contracts traded of approximately 274 million and crypto notional trading volumes of about $14 billion for the month. Event contracts traded came in at approximately 5.2 billion.

Full June operating data will be released alongside second-quarter earnings.

HOOD Shares Are ClimbingHOOD Price Action: Robinhood shares were up 8.42% at $108.72 at the time of publication on Wednesday, according to Benzinga Pro.

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

ConocoPhillips is a global oil giant with operations spanning 14 different countries. Occidental Petroleum recently sold off its chemical business and is pivoting toward high-tech carbon capture technologies.

July 01, 2026 16:05 ET  | Source: Scorpio Tankers Inc.

MONACO, July 01, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has issued a redemption notice for its 7.5% Senior Unsecured Notes due 2030 and received a commitment for a new credit facility.

Redemption of 7.5% Senior Unsecured Notes

The Company has issued a redemption notice to redeem its outstanding 7.5% Senior Unsecured Notes (the “Notes”). The Notes have an aggregate principal amount outstanding of $200 million, bear a coupon rate of 7.5% and were originally scheduled to mature in January 2030. The Notes are expected to be redeemed on July 17, 2026 at a make-whole price of 106.4 to par plus accrued but unpaid interest.

New Credit Facility

The Company has received a commitment from Standard Chartered Bank and DekaBank Deutsche Girozentrale for a credit facility of up to $90 million (the “Credit Facility”). The Credit Facility will be used to finance a portion of the purchase price of four scrubber-fitted MR newbuilding product tankers, which are currently under construction at Jingjiang Nanyang Shipbuilding Co., Ltd. in China with expected deliveries in 2026 and 2027. The Credit Facility has a final maturity of seven years from the delivery date of each vessel and bears interest at SOFR plus a margin of 1.20% per annum.

The terms and conditions of the Credit Facility, including financial covenants, are similar to those set forth in the Company’s existing credit facilities. The Credit Facility is subject to customary conditions precedent, and the execution of definitive documentation, and is expected to close within the third quarter of 2026.

About Scorpio Tankers Inc.

Scorpio Tankers Inc. is a provider of marine transportation of petroleum products worldwide. Scorpio Tankers Inc. currently owns 79 product tankers (29 LR2 tankers, 36 MR tankers and 14 Handymax tankers) with an average age of 10.2 years. The Company has reached agreements to sell one MR product tanker and four LR2 product tankers, which are expected to close in the third quarter of 2026. The Company has also reached agreements or letters of intent for six MR newbuildings that are currently under construction with deliveries expected in 2026, 2027 and 2030, four LR2 newbuildings with deliveries expected in 2027 and 2029 and two VLCC newbuildings with deliveries expected in 2028. Additional information about the Company is available at the Company’s website www.scorpiotankers.com, which is not a part of this press release.

Forward-Looking Statements

Matters discussed in this press release may constitute forward‐looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward‐looking statements in order to encourage companies to provide prospective information about their business. Forward‐looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “target,” “project,” “likely,” “may,” “will,” “would,” “could” and similar expressions identify forward‐looking statements.

The forward‐looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although management believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, there can be no assurance that the Company will achieve or accomplish these expectations, beliefs or projections. The Company undertakes no obligation, and specifically declines any obligation, except as required by law, to publicly update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward‐looking statements include unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, expansion and growth of the Company’s operations, risks relating to the integration of assets or operations of entities that it has or may in the future acquire and the possibility that the anticipated synergies and other benefits of such acquisitions may not be realized within expected timeframes or at all, the failure of counterparties to fully perform their contracts with the Company, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in the Company’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Company’s vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, the impact of the current and future sanctions that may impact the transportation of petroleum products, potential liability from pending or future litigation, general domestic and international political conditions, which have and may continue to disrupt certain global shipping routes, vessel breakdowns and instances of off‐hires, and other factors. Please see the Company’s filings with the SEC for a more complete discussion of certain of these and other risks and uncertainties.

Contact Information

Scorpio Tankers Inc.
James Doyle – Head of Corporate Development & Investor Relations
Tel: +1 203-900-0559
Email: [email protected]

, /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.

"Infants and young children with classic CAH face significant health challenges and are often exposed to high doses of glucocorticoids during critical periods of growth and development," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "The initiation of this Phase 2 study reflects our commitment to evaluating crinecerfont as a potential treatment option that could reduce the need for long-term supraphysiologic glucocorticoid use and help mitigate the associated risks in this vulnerable, very young population."

CAH is typically identified at or shortly after birth and can lead to life-threatening adrenal crises due to the underlying adrenal insufficiency, as well as androgen excess and consistent dosing of supraphysiologic glucocorticoids – complications for which there are no approved therapies in children under 4 years of age. Neurocrine is conducting this pediatric study under an FDA Pediatric Written Request.

The Phase 2 open-label, single-arm study consists of a 24-week treatment period with a primary objective of assessing the safety and tolerability of crinecerfont in 20 participants aged 3 months to under 4 years with classic CAH. Secondary objectives include evaluation of the pharmacokinetics and pharmacodynamic effects of crinecerfont on hormone biomarkers. This study is expected to support a planned supplemental New Drug Application to expand the approved U.S. indication to include patients less than 4 years of age. Additional information about the trial, including eligibility criteria, can be found at ClinicalTrials.gov.

Separately, Neurocrine achieved target enrollment for a Phase 2 study in the European Union to evaluate the safety and tolerability of crinecerfont in children from birth to under 2 years of age with classic CAH. For more information, visit ClinicalTrials.gov.

Crinecerfont was approved by the U.S. Food and Drug Administration in 2024, marking the first therapeutic advancement in more than 70 years for patients with classic CAH. It is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces elevated adrenocorticotropic hormone (ACTH) secretion at the source and the resulting downstream excess adrenal androgens through a non-GC mechanism.

About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.

Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).

About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.

CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients 4 to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.

Important Information

Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

IMPORTANT SAFETY INFORMATION

Do not take CRENESSITY if you:

Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.

CRENESSITY may cause serious side effects, including:

Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.

Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.

Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.

The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.

These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.

Please see full Prescribing Information.

About Neurocrine Biosciences, Inc. 
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc.

Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding our future development plans with respect to crinecerfont; the efficacy and therapeutic potential of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH); and the value and benefits CRENESSITY brings to adults and pediatric patients 4 years of age and older with CAH. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our product candidates may not occur or be submitted in a timely manner; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with U.S. federal or state legislative or regulatory and/or policy efforts which may result in, among other things, an adverse impact on our revenues or potential revenue; risks associated with potential generic entrants for our products; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

© 2026 Neurocrine Biosciences, Inc. All Rights Reserved.

SOURCE Neurocrine Biosciences, Inc.

TULSA, Okla.--(BUSINESS WIRE)--Williams (NYSE: WMB) today announced that its Board of Directors has appointed Lloyd W. “Billy” Helms, Jr. and Robb E. Turner as independent directors on the Board, effective July 1, 2026.

Helms brings more than 40 years of energy industry experience, most recently serving as president of EOG Resources, Inc., one of the largest exploration and production companies in the United States. During his career working across multiple divisions at EOG, he held several senior positions of increasing responsibility including chief operating officer from 2017 to 2023.

Turner has more than 35 years of energy operations, corporate finance and public and private equity and debt investment experience. He is chairman of The Madava Group and Revenant Energy and previously co-founded ArcLight Capital Partners, where he helped oversee investment, asset management, strategic planning and operations across the energy sector.

“We are pleased to welcome Billy and Robb to the Williams Board of Directors,” said Stephen W. Bergstrom, chairman of the Williams Board of Directors. “Williams is well positioned to support significant growth underway as demand for clean, reliable and affordable energy continues to increase. As we advance our natural gas-focused strategy, disciplined governance and experienced oversight remain central to our ability to create durable long-term value. Billy’s deep operational and technical experience across the energy sector and Robb’s broad background in energy operations, corporate finance and public and private energy investments will add valuable perspectives to the Board as we continue serving our customers, communities and shareholders.”

With the appointment of Helms and Turner, the Williams Board of Directors consists of 12 members, 11 of whom are independent.

About Billy Helms

Lloyd W. “Billy” Helms, Jr. has more than 40 years of oil and gas industry experience, including more than 15 years in executive leadership roles. He most recently served at EOG Resources, Inc., where he held several senior positions of increasing responsibility, including president from October 2021 to May 2024, chief operating officer from December 2017 to December 2023, executive vice president, exploration and production from August 2013 to December 2017, executive vice president, operations from February 2012 to August 2013, vice president and general manager of the Calgary, Alberta office from March 2008 to February 2012, and vice president, engineering and acquisitions from September 2006 to March 2008. In these roles, Helms led significant operational, technical, engineering and acquisition-related functions across EOG’s business. Helms joined the SM Energy Board of Directors in January 2026 upon the closing of the merger with Civitas Resources, Inc. and served on its Audit Committee. He currently serves as chair of the Operations and EHS Committee and as a member of the Compensation Committee. He previously served as an independent director of Civitas Resources. Helms holds a Bachelor of Science degree in petroleum engineering from Texas Tech University.

About Robb Turner

Robb E. Turner is chairman of The Madava Group, a holding company with interests in private and public energy companies, real estate and consumer food products, and has more than 35 years of energy operations, corporate finance and public and private equity and debt investment experience. He currently serves as chairman of Revenant Energy, an East Texas natural gas upstream company, and previously served as chairman of Crowheart Energy prior to its sale to Williams Companies. Through his Madava family office, Turner has made 15 private energy investments since 2017 across upstream, midstream, natural gas pipelines, terminals and metal trading, successfully exiting 14 of those investments. Prior to Madava, Turner was senior partner and co-founder of ArcLight Capital Partners, a leading power and energy private equity firm, where he helped oversee investment, asset management, strategic planning and operations for ArcLight and its funds. During his career at ArcLight, the firm raised six funds and invested more than $17 billion of private equity across the energy sector. Before co-founding ArcLight in 2001, Turner held senior positions at Wall Street firms advising on buyouts, corporate finance structures, and mergers and acquisitions. Prior to his business career, Turner served as an officer in the United States Army as a combat engineer. Turner earned a Bachelor of Science in engineering from the U.S. Military Academy at West Point and a Master of Business Administration from Harvard Business School.

About Williams

Williams (NYSE: WMB) is a trusted energy industry leader committed to safely, reliably and responsibly meeting growing energy demand. We use our infrastructure to deliver one third of the nation’s natural gas to where it's needed most, supplying the energy used to heat our homes, cook our food and generate low-carbon electricity. For over a century, we’ve been driven by a passion for doing things the right way. Today, our team of problem solvers is leading the charge into the clean energy future. Learn more at www.williams.com.

Portions of this document may constitute “forward-looking statements” as defined by federal law. Although Williams believes any such statements are based on reasonable assumptions, there is no assurance that actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Reform Act of 1995. Additional information about issues that could lead to material changes in performance is contained in Williams’ annual and quarterly reports filed with the SEC.

July 01, 2026 16:05 ET  | Source: Tsakos Energy Navigation

20-vessel newbuilding program on schedule

Shuttle tanker Anfield DP to be delivered in July 2026 in South Korea

$3.5 billion in minimum secured revenues

ATHENS, Greece, July 01, 2026 (GLOBE NEWSWIRE) -- TEN Ltd. (NYSE: TEN) (“TEN” or the “Company”), a leading diversified tanker and LNG operator, today announced the order of a second LNG carrier at Hyundai Heavy Industries in South Korea, with expected delivery in the first quarter of 2029.

With this order, TEN’s newbuilding program reaches 20 vessels, the first of which, the Anfield DP, a DP2 Shuttle tanker, is scheduled for delivery in late July 2026 with a minimum 10-year employment to a U.S. oil major, which, through extension options could stretch to 20 years.

“We are delighted to expand our presence in the ever-evolving LNG sector, a market we are actively participating in since 2007. The growing global energy demand fueled by geopolitical developments has increased the need for LNG as an alternative source,” Mr. George Saroglou, TEN’s President & COO stated.

ABOUT TEN LTD.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN's diversified pro-forma energy fleet currently consists of 83 vessels, in excess of 11 million dwt.

FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company
Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
[email protected]

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis /Markella Kara
+212 661 7566
[email protected]

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--Unum Group (NYSE: UNM) has promoted Andrew Walker to Executive Vice President, Chief Customer Operations Officer. In this role, Walker will continue to lead the company's Customer Operations organization, overseeing the teams, capabilities and transformation efforts that support how Unum Group shows up for customers, partners and the businesses it serves. “Andrew has quickly made an impact by strengthening the way we serve customers and run our operations,”.

New York, New York--(Newsfile Corp. - July 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

WHAT IS THIS ABOUT: On June 8, 2026, Investing.com published an article entitled "Ensign Group stock tumbles after short seller report." The article stated that Ensign shares fell after "short seller Hunterbrook released a report alleging the nursing home operator's business model relies on inadequate patient care and gaming quality metrics." Further, the article stated that Hunterbrook "published findings from a five-month investigation claiming the company's profits depend on understaffing facilities while routing taxpayer dollars to executives and affiliates. The report alleges patients have suffered and died as a result."

On this news, Ensign's shares fell 8.15% on June 8, 2026.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303630

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- With summer here and Kentucky currently experiencing an extended heat wave, Kentucky American Water reminds customers of simple steps they can take to use water more efficiently and manage their water bills. From adjusting your watering schedule to fixing household leaks, every drop counts.

Here are some wise water tips for use inside and outside the home:

Water early in the morning, later in the day and even at night to minimize evaporation. As much as 30 percent of water can be lost by watering during midday. Make use of rainwater by collecting it in rain barrels for use on outdoor plants and gardens.   Check sprinkler heads to help ensure water isn't being wasted on pavement or unwanted areas.   Use a broom instead of a hose to clean patios, driveways and sidewalks.   Mulch garden beds to retain moisture and prevent weeds. A 2-inch to 3-inch layer is typically effective.   Set your mower blades higher. Grass cut to 2.5 to 3.5 inches is more drought-resistant and healthier overall.   Check for leaks. Even small leaks can waste thousands of gallons of water each year. Ten percent of homes have leaks that can waste 90 gallons or more per day.   Kentucky American Water customers can monitor water usage through MyWater, the company's customer self-service portal which provides up to two years of usage data. MyWater also contains information about budget billing, customer assistance programs and more.   For more tips and resources, visit Kentucky American Water's Wise Water Use page.

About American Water
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 18 military installations. American Water's approximately 7,000 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.

 For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.

About Kentucky American Water
Kentucky American Water, a subsidiary of American Water with approximately 150 dedicated employees, provides safe, clean, reliable and affordable water and wastewater services to approximately 550,000 people. 

For more information, visit Kentucky American Water's website and join Kentucky American Water on Facebook, X and Instagram.

SOURCE American Water

-

PALO ALTO, Calif.--(BUSINESS WIRE)--AppLovin Corporation, (NASDAQ: APP) (“AppLovin” or the “Company”) the leading marketing platform, today announced it will report financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026 after the U.S. stock market closes.

An accompanying webinar will take place at 2:00 PM PT / 5:00 PM ET on August 5, 2026 during which management will discuss the Company’s quarterly results and provide commentary on business performance. The webinar will be hosted by Adam Foroughi, Co-founder and Chief Executive Officer, and Matthew Stumpf, Chief Financial Officer.

The webinar may be accessed on the Company’s website at: https://investors.applovin.com or via webinar registration. A replay of the webcast will also be available under the Events & Presentations section of the Company’s Investor Relations website.

About AppLovin

AppLovin makes technologies that help businesses of every size connect to their ideal customers. The company provides end-to-end advertising solutions for businesses to reach, monetize and grow their global audiences. For more information about AppLovin, visit: www.applovin.com.

Source: AppLovin Corp.

More News From AppLovin Corp.

Back to Newsroom

New York, New York--(Newsfile Corp. - July 1, 2026) - WHY: New York, N.Y., July 1, 2026. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), of the important July 17, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Commvault securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Commvault class action, go to https://rosenlegal.com/cases/commvault-systems-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Commvault's ARR growth environment; pertinently, Commvault knew or recklessly disregarded that its ARR growth guidance failed to properly factor in crucial variables, such as the type of sale. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Commvault class action, go to https://rosenlegal.com/cases/commvault-systems-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303633

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

PITTSBURGH--(BUSINESS WIRE)--American Eagle Outfitters, Inc. (NYSE: AEO) today announced that after 25 years of service, Mike Mathias, Executive Vice President - Chief Financial Officer will transition to serve as a full-time non-executive strategic advisor to Jay Schottenstein, Executive Chairman of the Board and Chief Executive Officer, effective August 3, 2026.

Ravi Thanawala will succeed Mathias as Executive Vice President - Chief Financial Officer, also effective August 3, 2026. To ensure a seamless leadership transition, Mathias will collaborate closely with Thanawala through the remainder of AEO’s 2026 fiscal year and continue supporting Schottenstein through July 30, 2027.

“I want to extend my immense appreciation to Mike for his exceptional leadership and dedicated service. Mike’s history with AEO runs incredibly deep. He began his career with the company in 1998, and though his professional journey took him elsewhere for a time, his love for AEO’s brands and people ultimately brought him back in 2017, where his significant impact led to his promotion to CFO in 2020. Throughout his tenure, he has successfully guided our organization through a rapidly evolving retail landscape and a period of significant growth, which is why I’ve asked Mike to step into the role of strategic advisor to me. Mike’s financial expertise and strategic foresight have been instrumental in strengthening the foundation of our business, driving long-term value and positioning AEO for a bright future,” said Jay Schottenstein.

Schottenstein continued, “We are pleased to welcome Ravi Thanawala to the executive team. His extensive retail background, dynamic leadership style and proven track record of delivering operational excellence for consumer-facing brands will position us well for long-term success.”

"I am incredibly proud of the financial and operational milestones we have achieved during my time as CFO,” said Mike Mathias. “I want to thank Jay, the Board of Directors and my colleagues for their partnership and extend my appreciation to our exceptional finance team for their dedication and resilience. I leave the finance function in highly capable hands, backed by the deep bench strength of our talented leaders–and I have full confidence in AEO’s continued momentum in the marketplace as I support a smooth transition.”

Incoming Executive Vice President - Chief Financial Officer, Ravi Thanawala said, “American Eagle Outfitters, Inc. has been a premier specialty retailer for generations with longstanding market leadership, and I am honored to step into the role as CFO. I have long admired AEO's powerful portfolio of beloved lifestyle brands, including American Eagle and Aerie, as well as the disciplined financial foundation and strong operational framework that Jay, Mike and the team have established. My immediate priority is working with Mike to ensure a seamless transition that maintains organizational momentum. Looking ahead, I am excited to partner with Jay and leadership to accelerate long-term strategic initiatives, maintain financial discipline and unlock new avenues for profitable growth that will help to maximize value for our shareholders.”

In addition, AEO today reaffirmed its second quarter and full-year 2026 financial guidance, as previously announced in its earnings release on May 28, 2026.

About Ravi Thanawala

Ravi Thanawala was appointed the Chief Financial Officer and President, North America of Papa John’s International, Inc. in November 2025 after serving as Chief Financial Officer and EVP, International since September 2024. Thanawala also served as Papa John’s Interim Chief Executive Officer from March 2024 to August 2024, after joining the company as Chief Financial Officer in July 2023. He previously held the role of Chief Financial Officer of Nike North America at Nike, Inc. from June 2020 to July 2023. From 2018 to 2020, Thanawala also served as the Global VP and CFO of the Converse brand. In addition, he was the Global VP of Retail Excellence from 2016 to 2018. Prior to Nike, Inc., Thanawala spent eight years at ANN INC. with progressively increasing responsibilities in finance and operations. He served in the finance leadership role for LOFT; led ANN INC’s Asia operations, global logistics and international trade based in Hong Kong; and rose to the position of CFO of the ANN INC. business, a subsidiary of Ascena Retail Group, Inc.

About American Eagle Outfitters, Inc.

American Eagle Outfitters, Inc. (NYSE: AEO) is a leading global specialty retailer with a portfolio of beloved apparel brands including American Eagle, Aerie, OFFL/NE by Aerie, Todd Snyder and Unsubscribed. Rooted in optimism, inclusivity and authenticity, AEO’s brands empower every customer to celebrate their unique personal style by offering casual, comfortable, timeless outfitting and high-quality products that are made to last.

AEO Inc. operates stores in the United States, Canada and Mexico, with merchandise available in more than 30 countries through a global network of license partners. Additionally, the company operates a robust e-commerce business across its brands. For more information, visit aeo-inc.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release and related statements by management contain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), which represent management’s expectations or beliefs concerning future events, including, without limitation, expected results for the second quarter and full-year fiscal 2026. Words such as “outlook,” "estimate," "project," "plan," "believe," "expect," "anticipate," "intend," “may,” “potential,” and similar expressions may identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements made by the company are inherently uncertain because they are based on assumptions and expectations concerning future events and are subject to change based on many important factors, some of which may be beyond the company’s control. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise and even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. The following factors, in addition to the risks disclosed in Item 1A., Risk Factors, of our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and in any other filings that we may make with the Securities and Exchange Commission, in some cases have affected, and in the future could affect, the company's financial performance and could cause actual results to differ materially from those expressed or implied in any of the forward-looking statements included in this release or otherwise made by management: the risk that the company’s operating, financial and capital plans may not be achieved; our inability to anticipate fluctuations in customer demand and respond to changing consumer preferences and fashion trends and to manage our inventory commensurately; the seasonality of our business; our inability to achieve planned store financial performance and gain market share in the face of declining shopping center traffic or attract customers to our stores; our inability to react to raw material cost, labor and energy cost increases; our inability to respond to changes in e-commerce and leverage omni-channel capabilities; our inability to execute on our key business priorities; our inability to expand internationally; difficulty with our international merchandise sourcing strategies; the impact that foreign trade issues, including import tariffs and other trade restrictions imposed by the U.S., China or other countries have had, and may continue to have, on our product costs, as well as continued uncertainty with respect to tariffs and other trade restrictions, the possibility that product costs may be affected by other foreign trade issues, such as currency exchange rate fluctuations, increasing prices for raw materials, supply chain issues, the potential for a trade war, political instability or other reasons; challenges with information technology systems, including safeguarding against security breaches; changes to U.S. or other countries' trade policies and tariff and import/export regulations, and global economic, public health, social, political and financial conditions, and the resulting impact on consumer confidence and consumer spending, as well as other changes in consumer discretionary spending habits, which could have a material adverse effect on our business, results of operations and liquidity.

The use of the “company,” “AEO,” “we,” "us," and “our” in this release refers to American Eagle Outfitters, Inc.

More News From American Eagle Outfitters, Inc.

SAN JOSE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Following its agreement to acquire Palm Mutual Water Company (Palm Mutual) in May 2025 and subsequent approval by the California Public Utilities Commission, California Water Service (Cal Water) has completed the purchase of Palm Mutual’s water system assets and will now begin serving its customers through Cal Water’s Bakersfield District.

The Palm Mutual system serves an estimated 250 residents through 63 residential customer connections and is located just two miles from Cal Water’s Northeast Bakersfield Treatment Plant. Cal Water already serves Palm Mutual through a master meter interconnection, since Palm Mutual did not own or operate its own sources of supply. Cal Water plans to upgrade the system’s infrastructure over time to help support long-term water quality and reliability.

“We believe everyone should have access to safe, clean, reliable, and affordable water and that bringing Palm Mutual’s water system into our Bakersfield District will help its customers have the high-quality water they need for their everyday use and emergencies, both now and into the future,” said Martin A. Kropelnicki, Cal Water Chairman and CEO. “We welcome Palm Mutual’s customers to California Water Service and look forward to serving them.”

Cal Water, the largest subsidiary of California Water Service Group (NYSE: CWT), is regulated by the CPUC, which approved the acquisition in December 2025. Cal Water’s Bakerfield District already serves about 445,600 people through approximately 120,000 service connections in its own system and the City of Bakersfield water system, which it operates.

About California Water Service

California Water Service provides high-quality, reliable water utility services to more than 2.1 million people statewide through 500,000 service connections. Cal Water’s purpose is to enhance the quality of life for customers and communities. To do so, it invests responsibly in water and wastewater infrastructure, sustainability initiatives, and community well-being. The company’s 1,200 employees live by a set of strong core values and share a commitment to protecting the planet, caring for people, and operating with the utmost integrity. The utility, commemorating a century of service this year, has been named one of “America’s Most Responsible Companies” and one of the “World’s Most Trustworthy Companies” by Newsweek, a USA Top Workplace, and a Great Place to Work®. More information is available at www.calwater.com. 

This news release contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("PSLRA"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor" treatment established by the PSLRA. Forward-looking statements in this news release are based on currently available information, expectations, estimates, assumptions and projections, and our management's beliefs, assumptions, judgments and expectations about us, the water utility industry and general economic conditions. These statements are not statements of historical fact. When used in our documents, statements that are not historical in nature, including words like will, would, expects, intends, plans, believes, may, could, estimates, assumes, anticipates, projects, progress, predicts, hopes, targets, forecasts, should, seeks or variations of these words or similar expressions, are intended to identify forward-looking statements. Examples of forward-looking statements in this news release include, but are not limited to, statements describing Cal Water’s expectations regarding operating and investing in the Palm Mutual system. Forward-looking statements are not guarantees of future performance. They are based on numerous assumptions that we believe are reasonable, but they are open to a wide range of uncertainties and business risks. Consequently, actual results or outcomes may vary materially from what is contained in a forward-looking statement. Factors that may cause actual results or outcomes to be different than those expected or anticipated include, but are not limited to, our ability to integrate the business and operate the Palm Mutual water system in an effective and accretive manner as well as those described under the section entitled "Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, and our other Securities and Exchange Commission filings. In light of these risks, uncertainties, and assumptions, investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact: Yvonne Kingman, 310-257-1434

--(BUSINESS WIRE)--Edison International (NYSE: EIX): WHAT: Second Quarter 2026 Financial Results   WHEN: Thursday, July 30, 2026, 1:30-2:30 p.m. (PT)     NUMBERS: 888-673-9780 — for callers in the U.S. 312-470-0178 — for international callers   PASSCODE Edison   WEBCAST: www.edisoninvestor.com   REPLAY: In addition to the live conference call and webcast, a telephone replay will be available through August 13, 2026, at 6 p.m. (PT) at the following numbers: 800-685-6667 — for callers in the U.S.

Expanded program helps students build essential technology, financial and workforce skills through flexible, self-paced learning

, /PRNewswire/ -- Associated Banc-Corp (NYSE: ASB) ("Associated") today announced the launch of the second year of its AI Academy, an innovative summer learning program designed to introduce middle school and high school students to artificial intelligence, financial literacy and digital skills. Building on insights gained from a successful pilot program in 2025, the academy will offer a more flexible, self-paced learning experience for students.

Associated Bank AI Academy Developed by Associated Bank in partnership with the Boys & Girls Clubs of Greater Milwaukee and powered by Skillsoft, the program equips students with foundational knowledge of artificial intelligence while helping them understand how technology is shaping the future of work, finance and everyday life.

Student recruitment began the week of June 22 at numerous Boys & Girls Clubs of Greater Milwaukee locations, like Davis, Daniels-Mardak, Fitzsimonds, Hillside and Mary Ryan. Learning content began June 29.

"Artificial intelligence is rapidly transforming the world around us, and we believe students should have opportunities to develop the skills and understanding needed to navigate that future," said Terry Williams, executive vice president and chief information officer. "The success of last year's pilot reinforced the importance of creating accessible, engaging learning experiences that help students explore emerging technologies while also building financial confidence and critical thinking skills."

The 2026 AI Academy features three learning journeys designed to meet students where they are in their understanding of artificial intelligence and financial literacy. Participants will complete self-assessment that places them into the learning path best suited to their current knowledge level. Students will complete one journey during the summer, progressing through weekly content modules released each Monday.

Topics include:

What is artificial intelligence and how it works AI in games, social media and entertainment Machine learning fundamentals Data analysis and predictive thinking Financial literacy and budget awareness AI's role in finance and business Online safety and digital responsibility Ethical considerations surrounding AI Content is delivered through short, interactive modules that students can access anytime and anywhere using mobile-friendly technology. Depending on the learning level, students will engage with approximately 90 minutes to two hours of content each week.

"The evolution of this year's program reflects what we learned from students and families during our pilot," said Williams. "By creating an on-demand experience, we're giving participants greater flexibility while maintaining a structured learning journey that encourages continued engagement throughout the summer."

Associated AI and HR experts collaborated with Skillsoft to customize learning tracks and ensure age-appropriate content for middle school learners. An experienced educator also reviewed the curriculum to confirm alignment with student learning needs and developmental stages.

Participants will earn digital badges and achievements as they progress through the program and will continue to receive "AB Bucks" incentives for completing coursework, skill gains, engaging in optional content and participating in a pitch event at the academy's conclusion. The program will culminate in a "Student Pitch Showcase" event later this year, providing participants with an opportunity to demonstrate what they have learned.

ABOUT ASSOCIATED BANC-CORP

Associated Banc-Corp (NYSE: ASB) has total assets of approximately $50 billion and is the largest bank holding company based in Wisconsin. Headquartered in Green Bay, Wisconsin, Associated is a leading Midwest banking franchise, offering a full range of financial products and services from over 200 banking locations throughout Wisconsin, Illinois, Iowa, Minnesota, Missouri and Nebraska. The Company also operates loan production offices in Indiana, Kansas, Michigan, New York, Ohio and Texas. Associated Bank, N.A. is an Equal Housing Lender, Equal Opportunity Lender and Member FDIC. More information about Associated Banc-Corp is available at www.associatedbank.com.

Media Contact: Andrea Kozek
Vice President | Senior Manager, Public Relations
920-491-7518 | [email protected]

SOURCE Associated Banc-Corp

, /PRNewswire/ -- Alamo Group Inc. (NYSE: ALG) announced today that its Board of Directors has declared its quarterly dividend of $0.34 per share. Payment of the July dividend will be made on July 29, 2026, to shareholders of record at the close of business on July 16, 2026.

About Alamo Group
Alamo Group is a leader in the manufacture and sale of high-quality, purpose-built industrial and vegetation management equipment. We serve end-markets such as infrastructure building and maintenance, industrial construction, public works, land maintenance, agriculture and tree care. Our products are sold to independent equipment dealers and directly to contractors and municipalities. Product categories include vocational products (vacuum trucks, street sweepers, roadside safety equipment, excavators, and snow removal equipment) and light machinery (tractor mounted mowing equipment, land maintenance and recycling equipment) as well as related after-market parts and services. The Company operates two divisions: the Industrial Equipment Division and the Vegetation Management Division. Founded in 1969, the Company has approximately 3,800 employees and operates 27 manufacturing facilities in North America, Canada, Europe, Brazil and Australia. The corporate offices of Alamo Group Inc. are located in Seguin, Texas.

Forward Looking Statements
This release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. Among those factors which could cause actual results to differ materially are the following: adverse economic conditions which could lead to a reduction in overall market demand, supply chain disruptions, labor constraints, increasing costs due to inflation, disease outbreaks, geopolitical risks, including tariffs, trade wars, and the effects of the war in the Ukraine and the Middle East, competition, weather, seasonality, currency-related issues, and other risk factors listed from time to time in the Company's SEC reports. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

SOURCE Alamo Group Inc.